Special Issue "New Frontiers in the Management of Retroperitoneal Soft Tissue Sarcoma"

A special issue of Current Oncology (ISSN 1718-7729).

Deadline for manuscript submissions: 15 August 2022 | Viewed by 879

Special Issue Editor

Dr. Carolyn Nessim
E-Mail Website
Guest Editor
Division of General Surgery, The Ottawa Hospital, Ottawa, ON, Canada
Interests: melanoma; soft tissue sarcoma; GIST; gastric cancer; database research

Special Issue Information

Dear Colleagues,

Soft tissue sarcomas are a rare and heterogeneous group of tumors with more than 100 histological subtypes and comprise only 1% of all adult cancers. They are usually caused by a variety of factors, such as exposure to chemical compounds, radiation, infections, and genetic diseases. Sarcomas can be divided into two large families: sarcomas of the soft tissues (smooth and striated muscles, adipose tissue, nerves, etc.) and sarcomas of the bone. They can occur anywhere in the body, but mainly in the extremities and the retroperitoneum. This Special Issue will focus on soft tissue sarcomas in the abdomen, pelvis, and retroperitoneum. Different histological subtypes have different biological behaviors and patterns of spread. The management of this disease requires a multidisciplinary team approach consisting of a wide range of members, such as medical and radiation oncologists, surgical oncologists, pathologists, nuclear medicine specialists, radiologists, and molecular biologists. The sarcoma mortality rate is relatively high: the global survival after 5 years is around 65%. In recent years, there has been an improvement in survival due to the improvement of diagnostic tools and better knowledge about the biology of these cancers and surgical techniques. Less defined is the role of chemotherapy and radiotherapy in modifying prognosis both in the adjuvant and metastatic setting.

In this Special Issue, we invite original studies and review articles on the diagnosis, biology, staging, and nomograms, genetic and epigenetic aspects, epidemiology, and novel therapeutic options of sarcomas (surgery, medical oncology, and radiation). This Special Issue also encourages papers evaluating aspects related to the quality of life of patients with sarcomas and any therapies and/or support procedures to improve patients’ quality of life.

Dr. Carolyn Nessim
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • sarcoma
  • soft tissue sarcoma
  • retroperitoneal sarcoma
  • diagnosis
  • treatment
  • pathology
  • surveillance
  • surgery
  • chemotherapy
  • radiation

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Article
A Case Series of Metastatic Malignant Gastrointestinal Neuroectodermal Tumors and Comprehensive Genomic Profiling Analysis of 20 Cases
Curr. Oncol. 2022, 29(2), 1279-1297; https://doi.org/10.3390/curroncol29020109 - 21 Feb 2022
Cited by 2 | Viewed by 736
Abstract
Malignant gastrointestinal neuroectodermal tumor (GNET) is an ultra-rare soft tissue sarcoma, therefore often misdiagnosed and has no available standard treatment. Here, we report 3 cases of metastatic GNET with variable clinical courses. Our small case series as well as extensive literature review, further [...] Read more.
Malignant gastrointestinal neuroectodermal tumor (GNET) is an ultra-rare soft tissue sarcoma, therefore often misdiagnosed and has no available standard treatment. Here, we report 3 cases of metastatic GNET with variable clinical courses. Our small case series as well as extensive literature review, further support that GNET is a spectrum of diseases with variable inherent biology and prognosis. Surgical management in the setting of recurrent/metastatic disease may be appropriate for GNET with indolent nature. Response to systemic treatments including chemotherapy and targeted treatments is variable, likely related to heterogenous biology as well. Furthermore, we retrospectively identified 20 additional GNET cases from Foundation Medicine’s genomic database and expanded on their clinicopathological and genomic features. Comprehensive genomic profiling (CGP) with DNA and RNA sequencing of this cohort, in the course of clinical care, demonstrated recurrent EWSR1 chromosomal rearrangements and a sparsity of additional recurrent or driver genomic alterations. All cases had low tumor mutational burden (TMB) and were microsatellite stable. Full article
Show Figures

Figure 1

Back to TopTop